|
注册号: Registration number: |
ChiCTR2400085190 |
|
最近更新日期: Date of Last Refreshed on: |
2024-06-03 11:01:38 |
|
注册时间: Date of Registration: |
2024-06-03 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
认知行为干预对脑肿瘤患者及其照顾者创伤后成长的影响 |
|
Public title: |
Effects of a cognitive-behavioral intervention on post-traumatic growth in brain tumor patients and their caregivers |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
脑肿瘤患者主要照顾者创伤后成长认知行为干预方案的构建与应用 |
|
Scientific title: |
Construction and application of a cognitive-behavioral intervention program for post-traumatic growth in primary caregivers of brain tumor patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
申腾刚 |
研究负责人: |
申腾刚 |
|
Applicant: |
Tenggang Shen |
Study leader: |
Tenggang Shen |
|
申请注册联系人电话: Applicant telephone: |
+86 180 3103 6216 |
研究负责人电话:
Study leader's |
+86 180 3103 6216 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
shentenggang@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
shentenggang@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市越秀区流花路111号南部战区总医院120栋 |
研究负责人通讯地址: |
广东省广州市越秀区流花路111号南部战区总医院120栋 |
|
Applicant address: |
Building 120, General Hospital of southern theater command No. 111 Liuhua Road, Yuexiu District, Guangzhou City, Guangdong Province |
Study leader's address: |
Building 120, General Hospital of southern theater command No. 111 Liuhua Road, Yuexiu District, Guangzhou City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南部战区总医院 |
||
|
Applicant's institution: |
General Hospital of southern theater command |
||
|
研究负责人所在单位: |
南部战区总医院 |
||
|
Affiliation of the Leader: |
General Hospital of southern theater command |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
NZLLKZ2023065 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南部战区总医院科学研究伦理委员会 |
||
|
Name of the ethic committee: |
Scientific Research Ethics Committee of the General Hospital of the Southern Theater of Operations |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-12-05 00:00:00 | ||
|
伦理委员会联系人: |
周泉 |
||
|
Contact Name of the ethic committee: |
Zhou quan |
||
|
伦理委员会联系地址: |
广东省广州市越秀区流花路111号 |
||
|
Contact Address of the ethic committee: |
No. 111, Liuhua Road, Yuexiu District, Guangzhou, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 130 7306 9690 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南部战区总医院 |
||||||||||||||||||||||
|
Primary sponsor: |
General Hospital of southern theater command |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市越秀区南部战区总医院77栋 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Building 77, Southern Theater General Hospital, Yuexiu District, Guangzhou City, Guangdong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-expense |
||||||||||||||||||||||
|
研究疾病: |
创伤反应 |
||||||||||||||||||||||
|
Target disease: |
traumatic reaction |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探索构建针对脑肿瘤患者主要照顾者创伤后成长的认知行为疗法方案,实施并验证其在提升照顾着创伤后成长水平与降低照顾者负担的有效性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the construction of a cognitive behavioral therapy program for post-traumatic growth for primary caregivers of brain tumor patients, and to implement and validate its effectiveness in enhancing caregiving post-traumatic growth and reducing caregiver burden. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
将符合纳入标准的照顾者分为认知行为疗法组和常规教育组两组,聚焦创伤的认知行为疗法组主要内容包括认知重建、心理教育、行为改变、情绪调节、体验表达和成长经验修复,入院期间完成4次干预,出院一周内干预1次,共5次;而常规宣教组的主要内容包沟通病情和健康指导,但不包括聚焦创伤的行为认知疗法的任何有效治疗成分。且分别于基线期(入院24小时)以及干预结束、干预结束后1个月时进行评估。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Caregivers who met the inclusion criteria were divided into two groups: a cognitive behavioral therapy group and a conventional education group; the main components of the trauma-focused cognitive behavioral therapy group included cognitive reconstruction, psychoeducation, behavioral change, emotional regulation, experiential expression, and repair of the growth experience, with four interventions completed during the admission period, and one intervention within one week of discharge, for a total of five interventions, whereas the main components of the conventional education group consisted of communicating about the condition and providing health guidance, but did not include any of the effective treatment components of trauma-focused behavioral cognitive therapy. and were assessed at baseline (24 hours after admission) and at the end of the intervention, 1 month after the end of the intervention, respectively. |
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)与患者为雇佣关系。 (2)拒绝参加研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Employment relationship with the patient. (2) Refuses to participate in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-11-01 00:00:00至 To 2025-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-03-10 00:00:00 至 To 2024-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
使用spss26.0版本生成随机数序列。在随机分组前,从进入研究的患者获得知情同意。由独立于研究结果评估和统计分析的研究人员进行随机分配,分组代码结果将放置在不透明的信封中,以确保分组隐藏。确认入组后,信封将按照入组顺序进行分发,直到研究开始时才可查询每个分组代码的含义以查看分组状态。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number sequences were generated using spss version 26.0. Informed consent was obtained from patients entering the study prior to randomization into groups. Random assignment was performed by researchers independent of the outcome assessment and statistical analysis of the study, and group code results will be placed in opaque envelopes to ensure group concealment. After confirmation of enrollment, the envelopes will be distributed in the order of enrollment, and the meaning of each grouping code will not be available until the beginning of the study to check the grouping status. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
入组患者与进行治疗的医护人员无法使用盲法,但可确保对资料分析人员设盲。 |
|
Blinding: |
Patients enrolled and medical staff undergoing treatment cannot use the blinding method, but it can ensure that the data analysis personnel are blinded. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
临床试验公共管理平台 http://www.medresman.org.cn |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Clinical trial public management platform http://www.medresman.org.cn |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
一、病例记录表 二、临床试验公共管理平台(http://www.medresman.org.cn) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1.Case Record Form 2.Clinical trial public management platform (http://www.medresman.org.cn) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |